Navigation Links
Resverlogix Advances to Second Arm of Phase 1b/2a Clinical Trial
Date:10/21/2008

TSX Exchange Symbol: RVX

CALGARY, Oct. 21 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that the ongoing double blind placebo controlled Phase 1b/2a study in subjects with normal and low HDL is progressing as planned. The subjects in the first group receiving a low dose of RVX-208 show safety and tolerability. Thus the safety committee the has made a decision to commence the next cohort in which 24 subjects will receive treatment doses escalating each week, for a total of 4 weeks.

Donald J. McCaffrey, President and CEO of Resverlogix stated, "We are very pleased to be able to share this exciting clinical information with the Clinical Advisory Board at the American Heart Association meeting on November 8th."

Resverlogix will give an oral presentation during the American Heart Association Scientific Sessions meeting in November 2008 where the Company will present novel data for RVX-208 to attendees. Due to the nature of double blinded clinical trials and strict embargo rules set by the American Heart Association, data from this Phase 1b/2a clinical trial will not be presented in full until the completion of the trial.

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT).

RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis. Major constituents of RCT include acceptors such as high-density lipoprotein (HDL) and apolipoprotein A-I (ApoA-I). A critical part of RCT is cholesterol efflux, in which accumulated cholesterol is removed from macrophages.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.


'/>"/>
SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Resverlogix Announces Closing of Debt Redemption
2. Resverlogix Eliminates Sixty Percent of Remaining Debt
3. Resverlogix Issues a Management Statement
4. Resverlogix Board of Directors Update
5. Resverlogix Notice of Conference Call & Webcast
6. Jan Gray Joins Resverlogix Board of Directors
7. Resverlogixs Lead Drug Featured in Key Scientific Publication
8. Industry Leaders Select Resverlogixs RVX-208
9. /C O R R E C T I O N from Source -- Resverlogix Corp./
10. Resverlogix Notice of Conference Call & Webcast
11. Resverlogix Share Option Extension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... The global Pyrogen Testing Market ... dominant share in the overall market. The leading players, ... Merck KGaA, held a lion,s share of 51% in ... that these companies are expected to retain their leadership ... do not require rabbit pyrogen testing along with strategic ...
(Date:11/30/2016)... , Nov. 30, 2016 Biotest Pharmaceuticals ... is pleased to announce the addition of its newest ... Kearney, Nebraska . The 15,200 square foot ... November 29th, 2016 and brings the total number of ... Ileana Carlisle , BPC,s Chief Executive Officer said ...
(Date:11/30/2016)... -  Equicare Health Inc ., the leading supplier of ... of the top 100 companies in the 2016 Global ... the top digital health companies across the globe.   ... year continually upgrading our product with the ongoing digital ... says Len Grenier , CEO of Equicare Health, ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 Novogene ... services and solutions with cutting edge next-generation sequencing (NGS) ... a USD $75 Million [515 Million RMB] B round ... Capital Management ( Shenzhen ) Co., Ltd. ... Innovation") and Shanghai Sigma Square Investment Center LP ("Sigma ...
Breaking Biology Technology:
(Date:11/29/2016)... 2016 BioDirection, a privately held medical device ... objective detection of concussion and other traumatic brain injury ... a meeting with the U.S. Food and Drug Administration ... Package. During the meeting company representatives reviewed plans for ... to commencement of a planned pilot trial. ...
(Date:11/28/2016)... LONDON , Nov. 28, 2016 ... at a rate of 16.79%" The biometric system ... to grow further in the near future. The biometric ... 32.73 billion in 2022, at a CAGR of 16.79% ... biometrics system, integration of biometric technology in smartphones, rising ...
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... LiveWire Healthcare and Life Sciences Awards as "Most ... off an unprecedented year of recognition and growth for ... over 15 years. iMedNet ™ ...
Breaking Biology News(10 mins):